Study Name:
Liberty AIRED Study
Targeted Disease(s):
Asthma
Purpose of Study:
To Evaluate the Efficacy and Safety of Dupilumab in Participants with Allergic Bronchopulmonary Aspergillosis.
Study Dates:
September 15, 2020 - October 23, 2023
Study Design:
Controlled Design
Study Location:
Nationwide
Funding Source:
Regeneron Pharmaceuticals, Inc.
Sponsors:
Regeneron Pharmaceuticals, Inc.
ClinicalTrails.gov Identifier:
NCT04442269
Contact:
Name: Clinical Trials Administrator
Phone: 844-734-6643
Email: [email protected]
